Cancer Clinical Trials in Africa—An Untapped Opportunity: Recommendations From AORTIC 2019 Conference Special Interest Group in Clinical Trials

Abstract

Cancer is now a formidable health care burden in sub-Saharan Africa (SSA) due to lifestyle westernization and longer life expectancy. The exponential increase in cancer incidence coupled with high mortality rate is not comparable with that seen in westernized countries. To address global cancer disparity, globalization of cancer clinical trials to involve sub-Saharan Africa can serve as a platform where innovative targeted therapies can be made available to patients in the environ. In the 2019 African Organization for Research and Training in Cancer (AORTIC) conference held at Maputo, Mozambique, a group of clinical trialists spanning across multiple continents highlighted the opportunities in Africa for the conduct of cancer clinical trials. The secondary purpose of the meeting was to address the belief that Africa was incapable of conducting interventional cancer trials but showed the in-continent strengths, such as available capacities, trained local clinical trialists with clinical trial experiences, clinical trial consortia, local capabilities, mapping out logistics, ethical consideration, political will, real-time benefits of clinical trials to clinical practice, and future directions for trials.

Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer

“…Yet, global geographical disparities remain in cancer clinical trials for PWH due to the exclusion of sub-Saharan African and Latin American countries—where the burden of HIV and HIV-associated cancers is highest—from cancer clinical trials. 52 Notably, there was a low proportion of black participants in these studies, highlighting previously demonstrated disparities in clinical trial enrollment among racial and ethnic minorities even in high-income countries. 53 54 Expanding ICI clinical trial enrollment for PWH is an important step in reducing barriers to immunotherapy access.…”

The Natural History and Treatment of Meningiomas: An Update

“…Organized neuro-oncology groups and highly specialized brain tumor centers from high performing countries should collaborate with institutions in low-performing regions to build capacity and improve the quantity and quality of experimental neuro-oncology research. 84…”

“…Simpson grading scale with related RFS after surgery to underrepresented and low-resource regions. Organized neuro-oncology groups and highly specialized brain tumor centers from high performing countries should collaborate with institutions in low-performing regions to build capacity and improve the quantity and quality of experimental neuro-oncology research 84. PrognosisMeningiomas generally have a good prognosis, which highly correlates with the histological grade, degree of resection, tumor size, and location.…”

Innovative Strategies for Developing Biomarker-Informed Cancer Clinical Trials to Accelerate Progress in Precision Oncology in Sub-Saharan Africa

“…However, there are few trained oncology specialists, low funding for research, and inadequate interprofessional collaboration to sustain patient-centered care. 5 6 there is now a critical mass of experienced personnel conducting clinical trials in communicable diseases such as malaria, tuberculosis, HIV, and neglected tropical diseases. Such expertise could be tapped for ongoing support and in-country experiential training for cancer clinical trial teams, because the understanding of challenges in conducting pragmatic clinical trials in low-and middle-income countries is already there.…”